TIMD4 anticorps (PE)

N° du produit ABIN2663932

Détail du produit anti-TIMD4 anticorps (PE)

Antigène: TIMD4 (T-Cell Immunoglobulin and Mucin Domain Containing 4 (TIMD4))

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp TIMD4 est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Clone: RMT4-54

Isotype: IgG2a kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TIMD4

Antigène: TIMD4 (T-Cell Immunoglobulin and Mucin Domain Containing 4 (TIMD4))

Autre désignation: Tim-4 (TIMD4 Produits)

Synonymes: anticorps RGD1564516, anticorps MGC99322, anticorps TIMD4, anticorps B430010N18Rik, anticorps TIM-4, anticorps Tim4, anticorps SMUCKLER, anticorps TIM4, anticorps T-cell immunoglobulin and mucin domain containing 4, anticorps T-cell immunoglobulin and mucin domain containing 4 L homeolog, anticorps T cell immunoglobulin and mucin domain containing 4, anticorps Timd4, anticorps TIMD4, anticorps timd4.L

Sujet: Tim-4 is a transmembrane protein known as T cell immunoglobulin and mucin domain containing protein-4. It is expressed on antigen-presenting cells and not on T cells. Tim-4 binds to Tim-1 to promote T cell proliferation by enhancing cell division and reducing apoptosis. Tim-4 bind to phosphatidylserine through its FG-CC' binding cleft in the N-terminal IgV domain to facilitate the clearance of apoptotic cells or bodies.

Pathways: Cancer Immune Checkpoints